October 26, 2021 |
*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform
Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.
Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.
New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.
Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.
“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”
At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).
In its first year, Mind+Matter also launched Gravity.ai – a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.
Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”
Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.
This content was provided by Inizio
Latest Content from Inizio
Download our pre-launch checklist
The key to conducting effective rare disease research
Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj
Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As...
Our latest infographic outlines the changes to the clinical trial process, accelerated drug approval, fast track of rare disease products and access opportunities in China's evolving healthcare environment.Find out more here-...
Research Partnership were delighted to exhibit, sponsor and present three papers at the EphMRA conference where Director Richard Head was presented with one of this year's MR Excellence Awards.Find out...
Research Partnership's client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just...
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients...
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland.
